A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Inclusion Criteria:

1. Females of 18 years of age or older at study screening
2. Histologically or cytologically confirmed locally advanced or advanced metastatic breast cancer that is not amenable to curative surgical resection or radiation therapy
3. The subject has been diagnosed with ER-positive breast cancer in the local laboratory
4. The subject has HER2-negative breast cancer in the local laboratory
5. Menopausal status is not limited (including Premenopausal/perimenopausal/postmenopausal state)
6. No previous systemic anti-tumor treatment for locally advanced or metastatic breast cancer;
7. According to RECIST V1.1, the patient has at least one measurable lesion that has not been irradiated by radiotherapy and can be evaluated by CT/MRI; If only bone metastases are present, there must be at least one osteolytic bone lesion that can be evaluated by CT/MRI
8. ECOG performance status of 0 or 1
9. Adequate organ and marrow function.
10. The subject of childbearing potential must use one highly effective birth control method from the total duration of the study and 6 months after the last dose of study intervention.
11. Provide informed consent

Exclusion Criteria:

1. Previous treatment with CDK4/6 inhibitors
2. Subjects with known hypersensitivity to any component of GB491 or Letrozole
3. Patients with disease progression or recurrence during or within 1 year after completion of previous endocrine neoadjuvant or adjuvant therapy
4. Known active, uncontrolled, or symptomatic central nervous system metastasis, carcinomatous meningitis, or clinically manifested leptomeningeal disease, cerebral edema, spinal compression or/and tumor progressive growth
5. Visceral crisis
6. Patients with skin lesion only and radiographically non-measurable at baseline
7. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia
8. Major surgical procedure within 4 weeks of the first dose of study treatment or an anticipated need for major surgery, chemotherapy, radiotherapy, any other investigational drug or other anti-cancer therapy during the study
9. Patients who have been on bisphosphonates and denosumab therapy at a stable dose for less than 14 days prior to randomization
10. Patients who have received limited field radiotherapy in 2 weeks or extended field radiotherapy in 4 weeks before randomization or radiation with more than 30% of the bone marrow
11. Subjects use drugs or fruits containing strong inducers or inhibitors of CYP3A4/5, or drugs with narrow therapeutic window that are mainly metabolized by CYP3A4/5 in 14 days before randomization
12. Patients with long-term systematic use of corticosteroids
13. Any severe and/or uncontrollable medical conditions
14. Patients with severely impaired lung function
15. Known history of HIV infection or history of HIV seropositivity
16. Resting QTcF > 480 msec or there is a medical history of QTcF prolongation
17. Subjects have significant hepatic disease
18. Coagulation abnormalities
19. Refractory nausea and vomiting, inability to swallow the formulated product, or other disease or clinical status would preclude adequate absorption, distribution, metabolism, or excretion of GB491
20. Previous allogeneic bone marrow transplant
21. Inflammatory breast cancer;
22. Subjects with a history of other primary malignancies, except for non-melanoma skin cancer and cervical cancer in situ disease-free status ≥ 3 years
23. Lactating women
24. Unlikely to comply with study procedures, restrictions, and requirements
25. Judgment by the investigator that the patient should not participate into the study